Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease`

Roche reported the drug sefaxersen achieved statistically significant and clinically meaningful results in a Phase 3 test in immunoglobulin A nephropathy, or IgAN. This antisense oligonucleotide, which came from Ionis Pharmaceuticals, could offer advantages over other drugs currently available for treating this rare chronic disease of the kidneys. The post Phase 3 Data Could Make…

Read More

How to Buy and Sell AI in health care? Not Easy.

By MATTHEW HOLT It was not so  long ago that you could create one of those maps of health care IT or digital health and be roughly right. I did it myself back in the Health 2.0 days, including the old sub categories of the “Rebel Alliance of New Provider Technologies” and the “Frontier of…

Read More

Friday Links

“NHS will pay diet apps who help to slim patients with weight-loss drugs”AI is creating new math.Denmark economy and Novo Nordisk.CDC resignations continue.Employer strategies for reference-based pricing of provider reimbursement.

Read More